Alkermes (NASDAQ:ALKS) used its presentation at the J.P. Morgan Healthcare Conference to outline its positioning entering ...

Plymouth Meeting-based Harmony Biosciences expects its narcolepsy drug Wakix to surpass $1 billion in revenue as growth ...

Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...

PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...

Harmony Biosciences expects its narcolepsy treatment Wakix to reach a major sales milestone in 2026, but the Plymouth Meeting ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...

Alkermes' alixorexton has become the first drug in the orexin 2 receptor agonist class to show efficacy in phase 2 trials involving patients with both main subtypes of sleep disorder narcolepsy.

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks to buy according to Wall Street.

The latest announcement is out from Alkermes ( (ALKS) ).

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).